DoD Melanoma, Idea Award | W81XWH 22 MRP IA

DoD Melanoma Research Program (MRP) Idea Award (FY22) - FAQs

What is the DoD MRP Idea Award (FY22)?

The DoD Melanoma Research Program (MRP) Idea Award (FY22) is a Department of Defense funding opportunity intended to spark genuinely new and unconventional directions in melanoma research. It is designed for early-stage, untested ideas that may be high-risk but could lead to high-reward breakthroughs if successful.

What is the main goal of this award?

The main goal is to fund bold, innovative melanoma research concepts that could open new research avenues and meaningfully shift the field. The broader motivation is practical and mission-driven: improving melanoma knowledge, patient care, and treatment options within the Military Health System, with relevance to active-duty Service Members, Veterans, other military beneficiaries, and the general public.

What types of research ideas are encouraged?

The program emphasizes novelty and innovation over incremental progress. Competitive proposals are expected to introduce a new paradigm, challenge an established assumption, or approach a persistent melanoma problem from a distinctly different angle. Exploratory work is encouraged, including both hypothesis-driven and hypothesis-generating research, as long as the project is scientifically well-justified and well-designed.

Does the project need a hypothesis?

Not necessarily. The opportunity allows for both hypothesis-driven studies and hypothesis-generating research. However, applicants are still expected to provide a strong scientific rationale, a coherent study design, and a credible analysis plan that shows how interpretable results will be produced and how success will be measured.

How important are the FY22 Challenge Statement and Focus Areas?

They are central requirements. Proposed projects are expected to be clearly responsive to the program's FY22 Challenge Statement and must address at least one of the FY22 MRP Focus Areas (as referenced in the full announcement).

What does the program mean by "high-risk, high-reward"?

It refers to early-stage concepts that have not yet been validated and may have a higher chance of failure than incremental work, but that could produce outsized advances if they succeed. The idea can be unconventional, but it still needs to be testable and supported by a solid rationale and plan.

What kinds of proposals are discouraged or considered a poor fit?

The Idea Award is not intended to fund incremental extensions of previously published findings, continuation of an established research trajectory, or the next logical step in a well-developed line of work. It also discourages superficial claims of "innovation," such as simply applying an existing tool or concept to melanoma after it has already been used in another cancer area without a truly novel insight or transformative change in approach.

Is this award intended for scaling up established work?

No. The emphasis is on opening new research avenues rather than scaling up, refining, or continuing what is already known or already underway in an established research program.

What does "unrestricted eligibility" mean for this opportunity?

Eligibility is described as unrestricted, meaning it is broadly open to many applicant types, subject to any specific clarifications in the official eligibility text. Applicants should rely on the official announcement for the controlling eligibility requirements.

Who administers this funding opportunity?

The opportunity is administered by the Department of Defense, Department of the Army, U.S. Army Medical Research Acquisition Activity (USAMRAA).

What is the official name and funding opportunity number?

The opportunity is listed as "DoD Melanoma, Idea Award" with Funding Opportunity Number W81XWH-22-MRP-IA.

What funding mechanism is used (grant or cooperative agreement)?

The announcement indicates awards may be made as either a grant or a cooperative agreement.

What is the CFDA/Assistance Listing number and category?

The program falls under CFDA/Assistance Listing 12.420 and is categorized under Science and Technology and other Research and Development.

When was this opportunity posted, and what were the deadlines listed?

The posting date is June 1, 2022. The original closing date listed is October 5, 2022.

How many awards are expected to be made?

The announcement anticipates making about 13 awards.

What is the maximum award amount (award ceiling)?

The summary field lists the award ceiling as 0. This typically indicates that applicants should rely on the full solicitation for actual budget limits or detailed funding guidance, rather than the summary listing.

What level of detail do reviewers expect in the research plan?

Even though the award supports bold and unconventional ideas, proposals are expected to be well-formed rather than vague. Reviewers will expect a strong scientific rationale, a coherent study design, and a credible analysis plan, including how the project will generate interpretable results and how success will be measured.

How should applicants think about "innovation" for this award?

Innovation is expected to be meaningful and transformative, not cosmetic. The opportunity is looking for ideas that change the way a melanoma problem is approached, challenge an assumption, or introduce a new paradigm, rather than simply repackaging existing approaches or transplanting a tool from another cancer area without a truly novel insight.

Who is the research expected to benefit?

The program emphasizes relevance to the Military Health System and populations it serves, including active-duty Service Members, Veterans, other military beneficiaries, and also the general public.

Where should applicants look for the definitive requirements?

The summary repeatedly points to the full announcement as the authoritative source, especially for the FY22 Challenge Statement, FY22 MRP Focus Areas, eligibility clarifications, and budget limits or funding guidance.